| 2019 | Family Studies of Whim Syndrome. (ASH Annual Meeting Abstracts). Annual Meeting Abstracts. Blood 2019 | Abstract | Dale DC, Dick E, Kelley ML, Makaryan V, Connelly J, Bolyard AA. |
| 2018 | Determination of phase 3 Dose for X4P-001 in patients with WHIM syndrome. (ASH Annual Meeting Abstracts). Blood 2018 | Abstract | Dale D, Firkin F, Bolyard A, Dick E, Hartmann S, Brown K, Ebrahim T, Gorelick KJ, Parasuraman S. |
| 2018 | Phase 2 study of X4P- 001: A targeted oral therapy for patients with WHIM syndrome. (European Hematology Association [EHA] Meeting Abstracts). Haematologica. (in press) | Abstract | Dale DC, Firkin F, Bolyard AA, Dick E, Kelley ML, Makaryan V, Niland K, Ebrahim T, Parasuraman S. |
| 2017 | X4P-001: a novel molecularly-targeted oral therapy for WHIM syndrome. (ASH Annual Meeting Abstracts). Blood 2017; 130:995 | Abstract | Dale DC, Bolyard AA, Dick E, Kelley ML, Makaryan V, Johnson R, Gan L, Parasuraman S. |
| 2012 | Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71. PMCID: PMC3585856. | Journal Article | Beaussant Cohen S, Fenneteau O, Plouvier E, Rohrlich PS, Daltroff G, Plantier I, Dupuy A, Kerob D, Beaupain B, Bordigoni P, Fouyssac F, Delezoide AL, Devouassoux G, Nicolas JF, Bensaid P, Bertrand Y, Balabanian K, Chantelot CB, Bachelerie F, Donadieu J. |
| 2012 | Tetralogy of fallot is an uncommon manifestation of warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. J Pediatr. 2012;161(4):763-5. PMCID: PMC3458406. | Journal Article | Badolato R, Dotta L, Tassone L, Amendola G, Porta F, Locatelli F, Notarangelo LD, Bertrand Y, Bachelerie F, Donadieu J. |
| 2011 | Plerixafor is a potential therapy for myelokathexis, WHIM syndrome. The 16th Congress of European Hematology Association. June 2011. | Abstract | Dale DC, Bolyard AA, Kelley ML, Westrup EC, Makaryan V, Aprikyan A, Wood B, Hsu F. |
| 2011 | The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome: Brief Reports. Blood. 2011;118:4963-6. PMCID: PMC3673761 | Journal Article | Dale DC, Bolyard AA, Kelley ML, Westrup EC, Makaryan V, Aprikyan A, Wood B, Hsu F. |
| 2011 | The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 2011 Nov 3;118(18):4963-6. doi: 10.1182/blood-2011-06-360586. Epub 2011 Aug 11. PMID: 21835955; PMCID: PMC3673761. | Journal Article | Dale DC, Bolyard AA, Kelley ML, Westrup EC, Makaryan V, Aprikyan A, Wood B, Hsu FJ. |